SNCA - Seneca Biopharma, Inc. Summary, Stock Quote and News | Benzinga

Market Overview

0.8299 0 (0%)

Data as of Aug 04, 2020

Prev. Close 0.8299
Price Open
Volume 0
Day's Range -
52 Wk Range 0.5 - 4.09
50 Day Moving Avg. 0.82
PE Ratio 0
Shares Outstanding 17.30M
Market Cap 14.36M

Trade SNCA stock for free with recommended broker TD Ameritrade.

Analyst Rating View All Ratings

Neuralsystem Shares Spike Higher After Company Granted U.S. Patent Number 10,702,555 Titled 'Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof;' Shares Up 8.1% Benzinga NewsdeskTue, 07 Jul 2020 13:51:29 -0400
20 Healthcare Stocks Moving In Wednesday's Pre-Market Session Benzinga InsightsWed, 17 Jun 2020 07:33:34 -0400
64 Biggest Movers From Yesterday Lisa LevinFri, 22 May 2020 05:26:41 -0400
51 Stocks Moving In Thursday's Mid-Day Session Lisa LevinThu, 21 May 2020 13:18:29 -0400
Seneca Biopharma Shares Halted On Circuit Breaker, Up 103% Benzinga NewsdeskThu, 21 May 2020 09:47:07 -0400
20 Healthcare Stocks Moving In Thursday's Pre-Market Session Benzinga InsightsThu, 21 May 2020 07:38:12 -0400
28 Stocks Moving in Thursday's Pre-Market Session Lisa LevinThu, 21 May 2020 07:17:15 -0400
20 Healthcare Stocks Moving In Monday's Pre-Market Session Benzinga InsightsMon, 18 May 2020 07:34:34 -0400
Seneca Biopharma shares are trading higher after the company reported Q1 EPS and sales results up from last year. Benzinga NewsdeskFri, 15 May 2020 08:39:46 -0400
Seneca Biopharma Q1 EPS $(0.930) Up From $(3.420) YoY, Sales $6.020M Up From $2.500K YoY Benzinga NewsdeskFri, 15 May 2020 08:05:22 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Seneca Biopharma Announces the Closing of its $5 Million Registered Direct Offering PRNewswireMay 27, 2020
Seneca Biopharma Reports Receipt of Warrant Exercise Proceeds PRNewswireMay 22, 2020
Seneca Biopharma Announces Pricing of $5 Million Registered Direct Offering Priced At-the-Market PRNewswireMay 22, 2020
Seneca Biopharma Reports 2020 First Quarter Results PRNewswireMay 15, 2020
Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS PRNewswireApr 09, 2020
Seneca Biopharma Announces Update on Phase II Clinical Trial Underway in China for the Treatment of Ischemic Stroke PRNewswireApr 07, 2020
Seneca Biopharma, Inc. Announces the Completion of Stem Cell Manufacturing Facility in China PRNewswireApr 03, 2020
Seneca Biopharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PRNewswireApr 01, 2020
Seneca Biopharma Announces Executive Appointments and Key Promotion PRNewswireApr 01, 2020
Seneca Biopharma, Inc. Reports Year End 2019 Fiscal Results PRNewswireMar 27, 2020
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Week in Review: Signs of Life After Coronavirus -- China Biopharma Scores $721 Million in Deals TalkMarketsApr 04, 2020
INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Seneca Biopharma, Inc. ... GuruFocusFeb 13, 2020
UCB's bimekizumab success in second late-stage psoriasis study Seeking AlphaNov 15, 2019
Seneca Biopharma reports Q3 results Seeking AlphaNov 14, 2019
Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen Seeking AlphaNov 03, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Earnings View Earnings

Q1 2020	EST	Actual	Surprise
EPS:	Expected 2020-05-15
Rev:	Expected 2020-05-15

Q2 2020	EST	Actual	Surprise
EPS:	Expected 2020-08-17
Rev:	Expected 2020-08-17

Company Profile

Read More

Visit company website

Start Investing

The Best Online Stock Trading Brokers

Best Free Stock Trading Brokers

Best Forex Brokers

Best Futures Brokers

How to Invest in Real Estate

Best Day Trading Courses

Brokerage Center

Compare All Online Brokerages